<DOC>
	<DOCNO>NCT00640510</DOCNO>
	<brief_summary>The primary objective study confirm efficacy IM olanzapine patient schizophrenia great IM placebo compare change baseline 2 hour post first IM injection agitation .</brief_summary>
	<brief_title>A Study Comparing Rapid Acting Intramuscular Olanzapine Placebo Agitated Patients With Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Polystyrene sulfonic acid</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Patients meet Diagnostic Statistical Manual Mental Disorders Fourth Edition , Text Revision ( DSMIVTR ) criterion schizophrenia . Male female , least 20 year less 65 year old . Inpatients study . Each patient , proxy consenter , understand nature study must sign informed consent document . The patient able cooperate study procedure view investigator . Patients consider , investigator subinvestigator , clinically agitated appropriate candidate treatment intramuscular ( IM ) medication . The investigator must believe safe administer IM olanzapine patient respect safety profile , include anticholinergic property Olanzapine IM . Patients minimum total score ≧ 20 five item Positive Negative Syndrome ScaleExcited Component ( PANSSEC ) use 17 scoring system prior first injection study drug . Patients score 1 2 AgitationCalmness Evaluation Scale ( ACES ) prior first injection study drug . Patients previously treat oral olanzapine consider treatmentresistant oral olanzapine , opinion investigator . Patients history allergic reaction intolerance study medication . Patients show evidence clinically significant bradycardia arrhythmia obtain either physical exam electrocardiogram ( ECG ) . Patients require concomitant treatment medication primary central nervous system activity , allow specified section `` concomitant treatment '' . Patients acute , serious unstable medical condition , include ( limited ) hepatic insufficiency ( specifically degree jaundice ) , recent cerebrovascular accident , uncontrolled seizure disorder , serious acute systemic infection immunologic disease , unstable cardiovascular disorder ( include ischemic heart disease ) , renal , gastroenterologic , respiratory , endocrinologic , neurologic , hematologic disease . Patients inadequately control diabetes , patient whose treatment diabetes change within 4 week prior first injection study drug . The investigator 's discretion supersede even patient meet criterion concurrent diabetes . Patients know neutrophil count total segment cell band cell count &lt; 1,500 /millimeter cubed ( mm3 ) . Patients know alanine aminotransferase/serum glutamic pyruvic transaminase ( ALT/SGPT ) value ≧2 time normal upper limit perform laboratory ( ULN ) aspartate aminotransferase/serum glutamic oxaloacetic transaminase ( AST/SGOT ) value ≧3 time ULN total bilirubin value ≧1.5 time ULN . Patients know serum triglyceride ≧500 milligrams/deciliter ( mg/dL ) . Electrocardiogram abnormality consider clinically significant investigator . Patients treatment injectable depot antipsychotic within one injection interval prior study drug administration . Patients receive treatment antipsychotic prohibit concomitant medicine show section `` prohibit concomitant medicine '' within 2 hour prior first IM study drug administration . Patients treatment benzodiazepine within 4 hour prior first IM study drug administration . Patients administer epinephrine within 24 hour prior first IM study drug administration . Patients receive treatment psychostimulants reserpine within 7 day prior first IM study drug administration . Patients receive beta blocker calcium channel blocker previously , must take medication dose 28 day prior first IM study drug administration . No beta blocker calcium channel blocker may administer within 24 hour first IM study drug injection , time double blind phase .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>August 2009</verification_date>
</DOC>